UCB has announced new week 16 results from the phase 3 BE BOLD trial showing that bimekizumab delivered superior joint ...

AstraZeneca has secured US approval for Baxfendy, a first‑in‑class aldosterone synthase inhibitor for adults whose ...

CellBxHealth has entered a collaboration with AdventHealth for the use of its Parsortix circulating tumour cell platform in ...

Microbiotica has announced positive findings from its phase 1b MELODY‑1 trial of MB097, an oral precision microbiome ...

The Scottish medicines consortium has recommended the reimbursement of enfortumab vedotin with pembrolizumab for adults with ...

Novo Nordisk has presented new sub‑analyses from the phase 3 OASIS 4 trial at ECO2026, showing that oral semaglutide 25mg ...

Calla Lily Clinical Care has dosed the first patients in its Freedom clinical trial, a nihr‑funded study evaluating the ...

The MHRA is establishing a new hub in Northern Ireland to support the region’s fast‑growing life sciences sector, in a move ...

PulseSight Therapeutics has unveiled positive phase 1 results for PST‑611, its non‑viral gene therapy candidate for dry ...

I’m sure many readers will relate to Kylie’s observation that approval procedures can unintentionally iron out the novel ...

Enterprise Therapeutics has reported that its phase 2 trial of ETD001, an investigational inhaled epithelial sodium channel ...

UCB has entered a new multi‑project strategic alliance with Cancer Research UK and its innovation arm, Cancer Research ...